The genetic risk factors for cerebral venous thrombosis: a case-control study in a Chinese national comprehensive hospital
About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES). Thirty-eight CVT patients hospitalized underwent WES. 977 subjects w...
Saved in:
Published in | Thrombosis journal Vol. 22; no. 1; pp. 50 - 11 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
17.06.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1477-9560 1477-9560 |
DOI | 10.1186/s12959-024-00621-8 |
Cover
Loading…
Abstract | About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES).
Thirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT.
Through analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT.
For CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response. |
---|---|
AbstractList | About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES).
Thirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT.
Through analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT.
For CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response. About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES). Thirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT. Through analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT. For CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response. About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES).BACKGROUNDAbout 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES).Thirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT.METHODSThirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT.Through analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT.RESULTSThrough analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT.For CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response.CONCLUSIONFor CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response. Abstract Background About 13–25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES). Methods Thirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT. Results Through analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT. Conclusion For CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response. Background About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to investigate genetic factors in CVT patients using whole exome sequencing (WES). Methods Thirty-eight CVT patients hospitalized underwent WES. 977 subjects with WES data from a community cohort study --the Shunyi cohort were as the control group. Using bioinformatics analysis, differential genes with rare damaging variants between two groups were filtered (P < 0.05). KEGG enrichment analysis was performed on the screened genes to identify pathways associated with CVT. Results Through analysis of medical history, routine tests, and imaging examinations, the etiology of 38 patients: 8 cases of antiphospholipid syndrome, 6 cases with hematologic diseases, 3 cases of protein C deficiency, and 2 cases of protein S deficiency. Five cases occurred during pregnancy or puerperium, and 3 cases had a history of oral contraceptive use, and so on. The etiology was unknown in 12 cases (31.6%), and the etiology of 4 patients were further clarified through WES: F9 c.838 + 1_838 + 16del, Hemizygote: F9 EX1-EX7 Dup; CBS c.430G > A, CBS c.949 A > G; F2 c.1787G > A; SERPINC1 c.409-11G > T. Comparing the WES data of two groups, a total of 179 different genes with rare damaging variants were screened (P < 0.05), with 5 genes of interest (JAK2, C3, PROC, PROZ, SERPIND1). Enrichment analysis of the 179 different genes revealed the complement and coagulation pathway and the mitogen activated protein kinases (MAPK) pathway were associated with CVT. Conclusion For CVT patients with unknown etiology, WES could help identify the cause of CVT early, which is of great significance for treatment decisions and prognosis. In addition to the complement and coagulation pathway, MAPK pathway is associated with CVT, potentially related to platelet regulation and inflammatory response. Keywords: Cerebral venous thrombosis, Whole exome sequencing, Risk factor, Hereditary thrombophilia, MAP kinase signaling pathway |
ArticleNumber | 50 |
Audience | Academic |
Author | Peng, Bin Yang, Xinzhuang Wang, Shaoying Yao, Ming Zhu, Yicheng |
Author_xml | – sequence: 1 givenname: Shaoying surname: Wang fullname: Wang, Shaoying – sequence: 2 givenname: Ming surname: Yao fullname: Yao, Ming – sequence: 3 givenname: Xinzhuang surname: Yang fullname: Yang, Xinzhuang – sequence: 4 givenname: Yicheng surname: Zhu fullname: Zhu, Yicheng – sequence: 5 givenname: Bin surname: Peng fullname: Peng, Bin |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38886735$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAUhSNURB_wB1ggS2zYpNhO_GKDqhEtlSqxKWvLca4nLok92JmRyq_H6bSogxDywtb1OZ98fc9pdRRigKp6S_A5IZJ_zIQqpmpM2xpjTkktX1QnpBWiVozjo2fn4-o05zuMKVWUvaqOGyklFw07qX7dDoDWEGD2FiWffyBn7BxTRi4mZCFBl8yIdhDiNqN5SHHqYvb5EzLImgy1jWFOcUR53vb3yIdSXw0-QAYUzOxjKG4bp02CAUL2O0BDzBs_m_F19dKZMcObx_2s-n755Xb1tb75dnW9uripLWv4XEvjesw6KsERolTDSIetZJ1VDeeEd8C4xI4BZQ1TxijZt7TtgLdSgC3XzVl1vef20dzpTfKTSfc6Gq8fCjGttUml_RG0MRacE4oRaVslOgXSCAZAMXbc9G1hfd6zNttugt5Cad6MB9DDm-AHvY47TcrECCcL4cMjIcWfW8iznny2MI4mQPli3WCBxdKaKNL3e-nalLf54GJB2kWuL4SSBLdMLsDzf6jK6mHyZTrgfKkfGN497-HP459CUQRyL7Ap5pzAaVvmtcyykP2oCdZL_vQ-f7rkTz_kT8tipX9Zn-j_Mf0GIUzesA |
CitedBy_id | crossref_primary_10_3892_mi_2025_218 |
Cites_doi | 10.1371/journal.pone.0203309 10.1049/syb2.12071 10.1101/gr.107524.110 10.1007/s11910-021-01124-z 10.1161/STROKEAHA.115.009843 10.1097/MD.0000000000000362 10.1182/blood.2023020788 10.1007/s00415-008-0958-8 10.1016/S0140-6736(82)90494-9 10.1016/j.jns.2013.10.009 10.1016/j.jstrokecerebrovasdis.2020.105145 10.1016/j.jtha.2023.06.029 10.1186/s12883-023-03455-5 10.1093/bioinformatics/btp324 10.1111/jth.14967 10.2174/1381612828666220526120515 10.1016/S1052-3057(98)80010-4 10.1016/j.cca.2021.05.012 10.1111/ijlh.14195 10.1136/bmjopen-2016-012351 10.1161/STR.0000000000000456 10.1074/jbc.271.12.6586 10.3389/fimmu.2021.671101 10.1182/blood-2016-11-749879 10.1016/j.jstrokecerebrovasdis.2020.105274 10.1182/blood-2002-03-0812 10.1038/nrneurol.2017.104 10.1007/s10545-016-9979-0 10.1007/s11910-014-0496-y 10.1161/01.STR.19.5.604 10.1111/ane.13032 10.1182/blood.V98.3.667 10.4049/jimmunol.0902765 10.37819/hb.2.1769 10.1212/01.wnl.0000296825.05176.da 10.1073/pnas.0910672106 10.21037/atm-20-4195 10.1093/bioinformatics/btr667 10.1182/blood-2009-07-233932 10.1161/STROKEAHA.107.490094 10.1007/s00415-005-0988-4 10.1038/gim.2015.30 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.1186/s12959-024-00621-8 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1477-9560 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_aaceff79518c497b9e8a75ee200f6ad4 PMC11181614 A798104584 38886735 10_1186_s12959_024_00621_8 |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: Capital Medical Development Research funding of China grantid: 2020-1-4012 – fundername: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences grantid: 2022-I2M-1-001 |
GroupedDBID | --- 0R~ 29Q 2WC 53G 5VS 6PF 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFS ACIHN ACUHS ADBBV ADRAZ ADUKV AEAQA AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M48 M~E O5R O5S OK1 OVT PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 FRP NPM PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c536t-8afd05b28ef1199351b0c85bc936616be5680f5e25359aa98d424be6487ec6be3 |
IEDL.DBID | M48 |
ISSN | 1477-9560 |
IngestDate | Wed Aug 27 01:32:23 EDT 2025 Thu Aug 21 18:33:36 EDT 2025 Fri Jul 11 10:16:00 EDT 2025 Tue Jun 17 22:09:38 EDT 2025 Tue Jun 10 21:15:38 EDT 2025 Wed Feb 19 02:05:51 EST 2025 Tue Jul 01 04:21:12 EDT 2025 Thu Apr 24 22:51:55 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Hereditary thrombophilia Whole exome sequencing MAP kinase signaling pathway Cerebral venous thrombosis Risk factor |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c536t-8afd05b28ef1199351b0c85bc936616be5680f5e25359aa98d424be6487ec6be3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/aaceff79518c497b9e8a75ee200f6ad4 |
PMID | 38886735 |
PQID | 3070793667 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_aaceff79518c497b9e8a75ee200f6ad4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11181614 proquest_miscellaneous_3070793667 gale_infotracmisc_A798104584 gale_infotracacademiconefile_A798104584 pubmed_primary_38886735 crossref_citationtrail_10_1186_s12959_024_00621_8 crossref_primary_10_1186_s12959_024_00621_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-06-17 |
PublicationDateYYYYMMDD | 2024-06-17 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-17 day: 17 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Thrombosis journal |
PublicationTitleAlternate | Thromb J |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | O Zloto (621_CR25) 2019; 139 KH Reuner (621_CR8) 2008; 70 C Lichy (621_CR33) 2006; 253 S Subramaniam (621_CR35) 2017; 129 F Adam (621_CR40) 2010; 115 M Leal Rato (621_CR21) 2021; 21 G Saposnik (621_CR1) 2024 B Voetsch (621_CR7) 2008; 39 S Dunjic Manevski (621_CR29) 2023 Q Wang (621_CR44) 2023; 17 621_CR26 T Turkut Tan (621_CR27) 2023; 21 J Saklatvala (621_CR39) 1996; 271 X Li (621_CR10) 2018; 13 JM Coutinho (621_CR22) 2015; 46 A Artoni (621_CR32) 2014; 14 V Marin (621_CR42) 2001; 98 E Meppiel (621_CR23) 2015; 94 621_CR41 A Lambrianides (621_CR43) 2010; 184 G Saposnik (621_CR3) 2024; 55 I Cotlarciuc (621_CR9) 2016; 6 JC van Swieten (621_CR13) 1988; 19 Y Dai (621_CR38) 2022; 28 V Le Cam-Duchez (621_CR5) 2008; 255 M Alet (621_CR2) 2020; 29 Chinese Society of Neurology CSS (621_CR12) 2020; 53 F Han (621_CR14) 2020; 8 B Zhang (621_CR20) 2021; 12 C Oury (621_CR37) 2002; 100 H Li (621_CR15) 2009; 25 PF Finelli (621_CR24) 1998; 7 SM Silvis (621_CR4) 2017; 13 S Richards (621_CR18) 2015; 17 AAM Morris (621_CR30) 2017; 40 M Athar (621_CR34) 2021; 519 P Patel (621_CR36) 2020; 18 M Choi (621_CR11) 2009; 106 M Sarov (621_CR28) 2014; 336 PM Mannucci (621_CR31) 1982; 2 FA San Lucas (621_CR17) 2012; 28 Q-H Li (621_CR6) 2023; 23 Y-T Wu (621_CR19) 2020; 29 A McKenna (621_CR16) 2010; 20 |
References_xml | – volume: 13 start-page: e0203309 issue: 8 year: 2018 ident: 621_CR10 publication-title: PLoS ONE doi: 10.1371/journal.pone.0203309 – volume: 17 start-page: 212 issue: 4 year: 2023 ident: 621_CR44 publication-title: IET Syst Biol doi: 10.1049/syb2.12071 – volume: 20 start-page: 1297 issue: 9 year: 2010 ident: 621_CR16 publication-title: Genome Res doi: 10.1101/gr.107524.110 – volume: 21 start-page: 41 issue: 8 year: 2021 ident: 621_CR21 publication-title: Curr Neurol Neurosci doi: 10.1007/s11910-021-01124-z – volume: 46 start-page: 2735 issue: 10 year: 2015 ident: 621_CR22 publication-title: Stroke doi: 10.1161/STROKEAHA.115.009843 – volume: 94 start-page: e362 issue: 1 year: 2015 ident: 621_CR23 publication-title: Med (Baltim) doi: 10.1097/MD.0000000000000362 – ident: 621_CR41 doi: 10.1182/blood.2023020788 – volume: 255 start-page: 1521 issue: 10 year: 2008 ident: 621_CR5 publication-title: J Neurol doi: 10.1007/s00415-008-0958-8 – volume: 2 start-page: 463 issue: 8296 year: 1982 ident: 621_CR31 publication-title: Lancet doi: 10.1016/S0140-6736(82)90494-9 – volume: 336 start-page: 257 issue: 1–2 year: 2014 ident: 621_CR28 publication-title: J Neurol Sci doi: 10.1016/j.jns.2013.10.009 – volume: 29 start-page: 105145 issue: 10 year: 2020 ident: 621_CR2 publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/j.jstrokecerebrovasdis.2020.105145 – volume: 21 start-page: 2913 issue: 10 year: 2023 ident: 621_CR27 publication-title: J Thromb Haemost doi: 10.1016/j.jtha.2023.06.029 – volume: 23 start-page: 423 issue: 1 year: 2023 ident: 621_CR6 publication-title: BMC Neurol doi: 10.1186/s12883-023-03455-5 – volume: 25 start-page: 1754 issue: 14 year: 2009 ident: 621_CR15 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp324 – volume: 18 start-page: 2087 issue: 9 year: 2020 ident: 621_CR36 publication-title: J Thromb Haemost doi: 10.1111/jth.14967 – volume: 28 start-page: 2001 issue: 24 year: 2022 ident: 621_CR38 publication-title: Curr Pharm Des doi: 10.2174/1381612828666220526120515 – volume: 7 start-page: 211 issue: 3 year: 1998 ident: 621_CR24 publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/S1052-3057(98)80010-4 – volume: 519 start-page: 247 year: 2021 ident: 621_CR34 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2021.05.012 – year: 2023 ident: 621_CR29 publication-title: Int J Lab Hematol doi: 10.1111/ijlh.14195 – volume: 6 start-page: e012351 issue: 11 year: 2016 ident: 621_CR9 publication-title: BMJ Open doi: 10.1136/bmjopen-2016-012351 – year: 2024 ident: 621_CR1 publication-title: Stroke doi: 10.1161/STR.0000000000000456 – volume: 271 start-page: 6586 issue: 12 year: 1996 ident: 621_CR39 publication-title: J Biol Chem doi: 10.1074/jbc.271.12.6586 – volume: 12 start-page: 671101 year: 2021 ident: 621_CR20 publication-title: Front Immunol doi: 10.3389/fimmu.2021.671101 – volume: 129 start-page: 2291 issue: 16 year: 2017 ident: 621_CR35 publication-title: Blood doi: 10.1182/blood-2016-11-749879 – volume: 29 start-page: 105274 issue: 11 year: 2020 ident: 621_CR19 publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/j.jstrokecerebrovasdis.2020.105274 – volume: 100 start-page: 2499 issue: 7 year: 2002 ident: 621_CR37 publication-title: Blood doi: 10.1182/blood-2002-03-0812 – volume: 13 start-page: 555 issue: 9 year: 2017 ident: 621_CR4 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2017.104 – volume: 40 start-page: 49 issue: 1 year: 2017 ident: 621_CR30 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-016-9979-0 – volume: 14 start-page: 496 issue: 11 year: 2014 ident: 621_CR32 publication-title: Curr Neurol Neurosci doi: 10.1007/s11910-014-0496-y – volume: 19 start-page: 604 issue: 5 year: 1988 ident: 621_CR13 publication-title: Stroke doi: 10.1161/01.STR.19.5.604 – volume: 139 start-page: 166 issue: 2 year: 2019 ident: 621_CR25 publication-title: Acta Neurol Scand doi: 10.1111/ane.13032 – volume: 98 start-page: 667 issue: 3 year: 2001 ident: 621_CR42 publication-title: Blood doi: 10.1182/blood.V98.3.667 – volume: 55 start-page: e77 issue: 3 year: 2024 ident: 621_CR3 publication-title: Stroke doi: 10.1161/STR.0000000000000456 – volume: 184 start-page: 6622 issue: 12 year: 2010 ident: 621_CR43 publication-title: J Immunol doi: 10.4049/jimmunol.0902765 – volume: 53 start-page: 648 issue: 09 year: 2020 ident: 621_CR12 publication-title: Chin J Neurol – ident: 621_CR26 doi: 10.37819/hb.2.1769 – volume: 70 start-page: 129 issue: 2 year: 2008 ident: 621_CR8 publication-title: Neurology doi: 10.1212/01.wnl.0000296825.05176.da – volume: 106 start-page: 19096 issue: 45 year: 2009 ident: 621_CR11 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0910672106 – volume: 8 start-page: 1579 issue: 23 year: 2020 ident: 621_CR14 publication-title: Ann Transl Med doi: 10.21037/atm-20-4195 – volume: 28 start-page: 421 issue: 3 year: 2012 ident: 621_CR17 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr667 – volume: 115 start-page: 4083 issue: 20 year: 2010 ident: 621_CR40 publication-title: Blood doi: 10.1182/blood-2009-07-233932 – volume: 39 start-page: 303 issue: 2 year: 2008 ident: 621_CR7 publication-title: Stroke doi: 10.1161/STROKEAHA.107.490094 – volume: 253 start-page: 316 issue: 3 year: 2006 ident: 621_CR33 publication-title: J Neurol doi: 10.1007/s00415-005-0988-4 – volume: 17 start-page: 405 issue: 5 year: 2015 ident: 621_CR18 publication-title: Genet Med doi: 10.1038/gim.2015.30 |
SSID | ssj0022925 |
Score | 2.3197958 |
Snippet | About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims to... Background About 13-25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This study aims... Abstract Background About 13–25% of cerebral venous thrombosis (CVT) cases lack clear etiology, which may be associated with underlying genetic factors. This... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 50 |
SubjectTerms | Brain damage Care and treatment Cerebral venous thrombosis Complications and side effects Genetic aspects Health aspects Hereditary thrombophilia Intracranial hypertension MAP kinase signaling pathway Oral contraceptives Risk factor Risk factors Venous thrombosis Whole exome sequencing |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NixQxEA2yB_Eiftu6SgTBg4SdTjrpxNsqLouwnlzYW0gyFWZg7V1mRg_-eqvS6WEaQS9eO5npdF6lX6VT9Yqxtw5ycNkmIZ3uRadiFDG2QTjVAtILclKgTwMXX835ZfflSl8dlPqimLBRHnicuJMQEuTcoyNgU-f66MCGXgMgutmEZVECRc6bNlN1qyWd1FOKjDUnW7ytdgL5SFDSYCvsjIaKWv-f7-QDUpoHTB4w0NkDdr-6jvx0HPJDdgeGR-zuRT0cf8x-IeQc7YHSEjmFjPNaTIejY8oTbOiM-Jr_LKqsnOojfI832_X2Aw88IZmJGrbOi-QsXw94ncprwxb49M2QUwj6BlZj2Dtf1aojT9jl2edvn85FLa0gklZmJ2zIy4WO0kJuKYRPt3GRrI7JKSRsE0Ebu8gapFbaheDsspNdBIPbG0jYrJ6yo-FmgOeMy2VYgCQZOJk7kIhXxL_D3kiNSYXcsHaaaZ-q7jiVv7j2Zf9hjR_R8YiOL-h427D3-9_cjqobf-39kQDc9yTF7HIB7chXO_L_sqOGvSP4Pa1rHF4KNT0BH5IUsvxp72xbTpUbdjzriesxzZrfTAbkqYmC2AZAYL0a5QiN6Rv2bDSo_ZiVtdb0SjfMzkxt9lDzlmG9KnLgLeUOo5f14n9Mw0t2T5ZlYkTbH7Oj3eYHvEK3axdflxX2G3v9LEE priority: 102 providerName: Directory of Open Access Journals |
Title | The genetic risk factors for cerebral venous thrombosis: a case-control study in a Chinese national comprehensive hospital |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38886735 https://www.proquest.com/docview/3070793667 https://pubmed.ncbi.nlm.nih.gov/PMC11181614 https://doaj.org/article/aaceff79518c497b9e8a75ee200f6ad4 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bixMxFA57AfFFvDu6lgiCDxLtZCY3QWQruyxCF1ksFF9Ckp7ZFupUp1XUX-9JZlp2cBFf-jDJpJk558yX5Fw-Qp4bqJypdGDcCMXKwnvmfe6YKXJAeEFMcvFoYHwuzyblh6mY7pEt3VH3AtfXbu0in9SkWb76-e3XOzT4t8ngtXy9xkGFYYg2LKYE5kzvk0NEJhWpHMblzqvAuUkkrHmZ3JZyuE2iuXaMHlClev5_f7WvwFY_pPIKRp3eJre6xSU9brXhDtmD-i65Me7c5_fIb1QKihoTExdpDCqnHd0OxaUrDdBEL_KS_kh1W2lkUPjiV-vF-g11NCDcsS6wnaaitHRR4_VIwA1roNtTRRqD1BuYt4HxdN7xktwnk9OTT-_PWEe-wIIo5IZpV82GwnMNVR6D_ETuh0ELH0yBkC49CKmHlQAuCmGcM3pW8tKDxA0QBGwuHpCDelXDI0L5zA2Bx0JxvCqBOxc8Doe9ETxD4aqM5Ns3bUNXmTwSZCxt2qFoaVvpWJSOTdKxOiMvd_d8bety_LP3KApw1zPW1E4XVs2l7UzU4rygqhQuOXUojfIGtFMCAL8jlXSzMiMvovht1EWcXnBdAgM-ZKyhZY-V0XnyO2fkqNcTLTb0mp9tFcjGphjmVgMK1hZtwUIpVUYetgq1m3OhtZaqEBnRPVXrPVS_pV7MU8HwPGYX4zrs8X_88RNykycrkCxXR-Rg03yHp7ju2vgB2VdTNSCHo5PzjxeDdHoxSAaGvxejz38ALn8uEQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+genetic+risk+factors+for+cerebral+venous+thrombosis%3A+a+case-control+study+in+a+Chinese+national+comprehensive+hospital&rft.jtitle=Thrombosis+journal&rft.au=Wang%2C+Shaoying&rft.au=Yao%2C+Ming&rft.au=Yang%2C+Xinzhuang&rft.au=Zhu%2C+Yicheng&rft.date=2024-06-17&rft.issn=1477-9560&rft.eissn=1477-9560&rft.volume=22&rft.issue=1&rft.spage=50&rft_id=info:doi/10.1186%2Fs12959-024-00621-8&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-9560&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-9560&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-9560&client=summon |